Perrigo Company
Perrigo Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine from Synthon
Published in Medical Letter on the CDC and FDA, September 28th, 2008
Perrigo Company (NASDAQ: PRGO) announced that it has acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the generic version of UCB's Xyzal(R) tablets, from Synthon Pharmaceuticals, Inc. Synthon believes it has a first to file ANDA application for the generic that can entitle it to 180 days of generic exclusivity upon approval. Synthon and UCB are currently engaged in Paragraph IV/Hatch-Waxman litigation over the Synthon ANDA filing.
Xyzal(R) is indicated for the treatment of indoor and outdoor allergies. It is estimated that it has annual sales of approximately $200 million dollars growing at 15% per year, according to data provided by...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Emory University
As head and neck cancer risks evolve, more treatment options emerge - Research
Help from herpes? Coinfection induces acyclovir to inhibit HIV - HIV/AIDS
New HIV/AIDS study findings reported from E. Seminari and co-authors - Life Sciences
Research from Stanford University provides new data about life sciences - MiCardia Corporation
MiCardia Corporation Receives US FDA Market Clearance for Dynaplasty Annuloplasty Devices - Regulatory Actions
New regulatory actions study findings reported from C.A. Stockl and co-authors - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
